~~<i id='05DF118F10'><strike id='05DF118F10'><tt id='05DF118F10'><pre id='05DF118F10'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：explore 2025-10-02 21:05:35 - browse：9766

Allergan, Dom Smith/STAT

It wasn’t supposed to work out this way for Brent Saunders.

Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： FDA early review: GLP

focus

leisure time

knowledge

hotspot

focus

PfizerviaAPAsaprimarycaredoctorinNewYorkCity,IamgratefultodrugcompaniesforprovidingeffectiveCovid-19

WSS

American taxpayers paid $1.8 trillion in health care costs in 2022

Merck to acquire Harpoon Therapeutics for $680 million

Chan Zuckerberg Biohub Chicago to focus on inflammation

Why age limits for politicians are a terrible idea

Arena BioWorks launches in Cambridge to speed drug discovery

Physician executives need more than on

hotspot

explore

focus

How one medical school became remarkably diverse

Phenylephrine and the overlooked value of the placebo effect

The cancer drug shortage isn’t new — and neither are the solutions

Senate panel eyes new effort on drug shortages

Dobbs anniversary: the lost opportunity of abortion as health care

Physician executives need more than on

New air purifier tech could be key to improving indoor air quality

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Life science postdocs should get big pay hike, NIH panel says

leisure time

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Sana to lay off nearly a third of staff, de

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Medicare Advantage overpayments discussion gets experts fired up

Stroke deaths set to near 10 million globally by 2050

Ascension's ugly legal battle over care for poor patients in Texas

knowledge

knowledge

hotspot

focus